Recludix Pharma Is A Biotechnology Company Dedicated To Discovering And Developing Selective Inhibitors That Target Challenging Protein Domainsparticularly Sh2 Domains Involved In Disease Signaling Pathwaysthe Company Utilizes A Proprietary Drug Discovery Platform That Combines Custom Generated Dna Encoded Librariesstructure Activity Relationship Determinationsand A Unique Screening Tool To Enhance The Selectivity Of Its Compounds Recludix S Product Pipeline Focuses On Oral Small Molecule Inhibitors Targeting The Jak Stat Signaling Pathwaywhich Plays A Role In Various Inflammatory And Immune Mediated Diseaseskey Programs Include A Stat6 Inhibitor Developed In Partnership With Sanofiaimed At Conditions Like Atopic Dermatitis And Asthmaand A Stat3 Inhibitor Targeting Diseases Such As Psoriasis And Rheumatoid Arthritisadditionallythe Company Is Advancing A Btk Inhibitor For Chronic Urticaria And Multiple Sclerosisrecludix S Innovative Approach Positions It As A Significant Player In Developing New Therapeutics For Chronic Inflammatory Diseases
No conferences found for this company.
| Company Name | Recludix Pharma |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
